Phase II study of alemtuzumab-rituximab therapy in previously untreated patients with chronic lymphocytic leukemia: Short- and long-term outcomes

Leukemia and Lymphoma

Volumn 56, Issue 2, 2015, Pages 315-323

  Frankfurt, Olga ^a   Ma, Shuo ^a   Gordon, Leo ^a   Winter, Jane N ^a   Horowitz, Jeanne M ^a   Rademaker, Alfred ^a   Weitner, Bing Bing ^a   Peterson, Loann C ^a   Altman, Jessica K ^a   Tallman, Martin S ^b   Petrich, Adam ^a   Rosen, Steven T ^c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Alemtuzumab; CLL; Immunotherapy; Rituximab

Indexed keywords

ALEMTUZUMAB; DIPHENHYDRAMINE; PARACETAMOL; PREDNISOLONE; RITUXIMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BACTERIAL INFECTION; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER STAGING; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; FATIGUE; FEMALE; HUMAN; HYPERTRANSAMINASEMIA; HYPOCALCEMIA; LYMPHADENOPATHY; MALE; MINIMAL RESIDUAL DISEASE; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PANCYTOPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SECOND CANCER; THROMBOCYTOPENIA; VERY ELDERLY; VIRUS REACTIVATION; CHEMICALLY INDUCED; CLINICAL TRIAL; FEVER; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MIDDLE AGED; PATHOLOGY; RASH; REMISSION; SURVIVAL ANALYSIS; TIME FACTOR; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; EXANTHEMA; FEMALE; FEVER; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; NEOPLASM STAGING; NEUTROPENIA; REMISSION INDUCTION; RITUXIMAB; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84923924098     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2014.910654     Document Type: Article

References (43)

1. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fl udarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010; 376: 1164-1174
2. Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fl udarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 4079-4088
3. Tam CS, O'Brien S, Wierda W, et al. Long-term results of the fl udarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008; 112: 975-980
4. Huhn D, von Schilling C, Wilhelm M, et al. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 2001; 98: 1326-1331
5. Schulz H, Klein SK, Rehwald U, et al. Phase 2 study of a combined immunochemotherapy using rituximab and fl udarabine in patients with chronic lymphocytic leukemia. Blood 2002; 100: 3115-3120
6. Stanglmaier M, Reis S, Hallek M. Rituximab and alemtuzumab induce a nonclassic, caspase-independent apoptotic pathway in B-lymphoid cell lines and in chronic lymphocytic leukemia cells. Ann Hematol 2004; 83: 634-645
7. Lundin J, Kimby E, Bjorkholm M, et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as fi rstline treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002; 100: 768-773
8. B D, Bennett J M, Grever M, et al. N ational Cancer Institutesponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990-4997
9. Chen YH, Peterson LC, Dittmann D, et al. Comparative analysis of fl ow cytometric techniques in assessment of ZAP-70 expression in relation to IgVH mutational status in chronic lymphocytic leukemia. Am J Clin Pathol 2007; 127: 182-191
10. Monaghan SA, Peterson LC, James C, et al. Pan B-cell markers are not redundant in analysis of chronic lymphocytic leukemia (CLL). Cytometry B Clin Cytom 2003; 56: 30-42
11. Knauf WU, Lissichkov T, Aldaoud A, et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009; 27: 4378-4384
12. E ichhorst B F, Busch R, Hopfi nger G, et al. Fludarabine plus cyclophosphamide versus fl udarabine alone in fi rst-line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006; 107: 885-891
13. Fischer K, Cramer P, Busch R, et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2012; 30: 3209-3216
14. Bottcher S, Ritgen M, Fischer K, et al. Minimal residual disease quantifi cation is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol 2012; 30: 980-988
15. Hillmen P, Skotnicki AB, Robak T, et al. Alemtuzumab compared with chlorambucil as fi rst-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007; 25: 5616-5623
16. Zent CS, Call TG, Shanafelt TD, et al. Early treatment of highrisk chronic lymphocytic leukemia with alemtuzumab and rituximab. Cancer 2008; 113: 2110-2118
17. Karlsson C, Norin S, Kimby E, et al. Alemtuzumab as fi rst-line therapy for B-cell chronic lymphocytic leukemia: long-term followup of clinical eff ects, infectious complications and risk of Richter transformation. Leukemia 2006; 20: 2204-2207
18. P losker G L, Figgitt D P. R ituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 2003; 63: 803-843
19. Tuthill M, Crook T, Corbet T, et al. Rapid infusion of rituximab over 60 min. Eur J Haematol 2009; 82: 322-325
20. Byrd JC, Waselenko JK, Maneatis TJ, et al. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side eff ects and rapid blood tumor clearance. J Clin Oncol 1999; 17: 791-795
21. O'Brien S, Ravandi F, Riehl T, et al. Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumabbased therapy. Blood 2008; 111: 1816-1819
22. M oreno Codgson K, Ferrer G, et al. A utoimmune cytopenia in chronic lymphocytic leukemia: prevalence, clinical associations, and prognostic signifi cance. Blood 2010; 116: 4771-4776
23. Hamblin TJ. Autoimmune complications of chronic lymphocytic leukemia. Semin Oncol 2006; 33: 230-239
24. E ngelfriet C P, Overbeeke M A, von dem B orne A E. A utoimmune hemolytic anemia. Semin Hematol 1992; 29: 3-12
25. Kyasa MJ, Parrish RS, Schichman SA, et al. Autoimmune cytopenia does not predict poor prognosis in chronic lymphocytic leukemia/ small lymphocytic lymphoma. Am J Hematol 2003; 74: 1-8
26. Mauro FR, Foa R, Cerretti R, et al. Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features. Blood 2000; 95: 2786-2792
27. Zent CS, Ding W, Schwager SM, et al. The prognostic signifi cance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphoma. Br J Haematol 2008; 141: 615-621
28. V isco C, Ruggeri M, Laura Evangelista M, et al. I mpact of immune thrombocytopenia on the clinical course of chronic lymphocytic leukemia. Blood 2008; 111: 1110-1116
29. R eda G, Maura F, Gritti G, et al. L ow-dose alemtuzumab-associated immune thrombocytopenia in chronic lymphocytic leukemia. Am J Hematol 2012; 87: 936-937
30. F an L, Wang L Z hang R, et al. R ichter transformation in 16 of 149 Chinese patients with chronic lymphocytic leukemia. Leuk Lymphoma 2012; 53: 1749-1756
31. Rossi D, Cerri M, Capello D, et al. Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome. Br J Haematol 2008; 142: 202-215
32. Tsimberidou AM, Keating MJ, Wierda WG. Richter's transformation in chronic lymphocytic leukemia. Curr Rhematol Malig Rep 2007; 2: 265-271
33. Parikh SA, Rabe KG, Call TG, et al. Diff use large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients. Br J Haematol 2013; 162: 774-782
34. F lynn J M, Andritsos L, Lucas D, et al. S econd malignancies in B-cell chronic lymphocytic leukaemia: possible association with human papilloma virus. Br J Haematol 2010; 149: 388-390
35. Schollkopf C, Rosendahl D, Rostgaard K, et al. Risk of second cancer after chronic lymphocytic leukemia. Int J Cancer 2007; 121: 151-156
36. Quaglino D, Di Leonardo G, Lalli G, et al. Association between chronic lymphocytic leukaemia and secondary tumours: unusual occurrence of a neuroendocrine (Merkell cell) carcinoma. Eur Rev Med Pharmacol Sci 1997; 1: 11-16
37. Manusow D, Weinerman BH. Subsequent neoplasia in chronic lymphocytic leukemia. JAMA 1975; 232: 267-269
38. Beiggi S, Johnston JB, Seftel MD, et al. Increased risk of second malignancies in chronic lymphocytic leukaemia patients as compared with follicular lymphoma patients: a Canadian population-based study. Br J Cancer 2013; 109: 1287-1290
39. D'A rena G, Gemei M, Luciano L, et al. C hronic lymphocytic leukemia after chronic myeloid leukemia in the same patient: two diff erent genomic events and a common treatment? J Clin Oncol 2012; 30: e327-e330
40. Buda-Okreglak EM, Cordaro DV. Simultaneous chronic myeloid leukemia and chronic lymphocytic leukemia. Blood 2011; 117: 5279
41. A lley C L, Wang E, Dunphy C H, et al. D iagnostic and clinical considerations in concomitant bone marrow involvement by plasma cell myeloma and chronic lymphocytic leukemia/monoclonal B-cell lymphocytosis: a series of 15 cases and review of literature. Arch Pathol Lab Med 2013; 137: 503-517
42. Morrison VA, Rai KR, Peterson BL, et al. Th erapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fl udarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011. J Clin Oncol 2002; 20: 3878-3884
43. Smith MR, Neuberg D, Flinn IW, et al. Incidence of therapyrelated myeloid neoplasia after initial therapy for chronic lymphocytic leukemia with fl udarabine-cyclophosphamide versus fl udarabine: long-term follow-up of US Intergroup Study E2997. Blood 2011; 118: 3525-3527.